52 North Health

What 52 North Health does

52 North Health is a Cambridge, UK-based medical technology company founded in 2018 as a spin-out from the University of Cambridge. It is developing a portfolio of in-vitro diagnostic and digital products built on its proprietary Aster™ platform — a patented lateral flow system capable of simultaneously measuring cell-based and soluble biomarkers from a single sample via an automated microfluidic process. The lead product, Neutrocheck®, is a portable finger-prick blood test paired with a companion app designed to detect neutropenic sepsis risk in chemotherapy patients by simultaneously measuring neutrophil count and C-reactive protein. ACORN™ is a web-based digital triage platform enabling real-time communication and clinical decision support between acute oncology nurses and patients, while ARC™, launched in 2025, extends the Aster™ platform to nuclear emergency preparedness and radiation sickness triage for defence and NATO applications. All three products are explicitly described as in development, not regulator-authorised, and not commercially available.

The company is pre-revenue with a B2B enterprise sales motion targeting healthcare systems, NHS trusts, pharmaceutical companies, and defence buyers. Expected revenue streams once commercialised include hardware and consumable sales for Neutrocheck®, subscription or licensing for ACORN™, co-development/licensing royalties from pharmaceutical and diagnostic partners, and defence contracts for ARC™. The company is piloting Neutrocheck® at multiple UK hospital sites including Addenbrooke's (with a 250-patient clinical trial planned) and has a 21-month collaboration with Cambridge University Hospitals NHS Foundation Trust, UK Sepsis Trust, Macmillan Cancer Support and UnifAI Technology. ACORN™ was co-developed with the East of England Cancer Alliance. A strategic collaboration with a global pharmaceutical company and co-development with one of the world's leading diagnostic companies for a remote platelet-measurement product indicate platform-licensing potential.

52 North Health has raised approximately $11M to date, anchored by a landmark $6M round in December 2024 co-led by KHP Ventures (UK) and Cedars-Sinai Intellectual Property Co. (US), the first transatlantic hospital-venture-fund co-led deal. Backers include Macmillan Cancer Support (its first-ever venture investment), Cancer Research Horizons, Meridian Health Ventures, OKG Capital, Cambridge Enterprise, NIHR grants, Innovate UK, and €400,000 from NATO DIANA. Neutrocheck® holds UK IDAP breakthrough status, and the company operates a ~20-person multidisciplinary team led by CEO Umaima Ahmad (former AstraZeneca billion-dollar oncology transactions) under Chair John Jeans CBE.

Name

52 North Health

Legal name

52 North Health Ltd

Website

https://52north.health

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

52 North Health is a Cambridge-based medtech company building the proprietary Aster™ diagnostic platform with three pre-commercial products: Neutrocheck® for cancer patient neutropenic sepsis monitoring, ACORN™ for acute oncology triage, and ARC™ for nuclear emergency preparedness.

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• In-vitro diagnostic devices
• Digital health platforms
• Point-of-care diagnostics
• Cancer care diagnostics
• Lateral flow assays

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales (Neutrocheck): Neutrocheck is a portable finger-prick blood test device that detects biomarkers from a biological specimen. Revenue will be generated through sales of the device and associated consumables to healthcare providers and patients. Products mentioned on the site are in development and not currently available for sale.
2. Digital Health Solutions (ACORN): ACORN is a web-based digital platform for acute oncology triaging. Revenue model likely subscription or licensing to healthcare providers and NHS trusts.
3. Pharmaceutical Partnerships: Aster platform can be used by pharmaceutical companies to support drug development, drug safety and drug targeting. For example, Neutrocheck can be used to enable at-home treatment monitoring in clinical trials. Revenue could come from licensing, co-development agreements, or service fees.
4. Co-development and Licensing: Strategic co-development opportunities with diagnostic companies. Working with one of the world's leading diagnostic companies to co-develop a new product that can remotely measure platelets using the Aster platform.
5. Defence Sector (ARC): New product ARC for nuclear emergency preparedness backed by NATO. €400,000 received from NATO DIANA programme. Revenue opportunity through defence contracts and commercial adoption by NATO countries.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

52 North Health develops in-vitro diagnostic medical devices and digital health solutions built on its proprietary Aster™ platform, which uses lateral flow technology to enable simultaneous measurement of cell-based and soluble biomarkers from a single sample. Its lead product Neutrocheck® is a portable finger-prick blood test and companion app that assesses neutrophil count and CRP to identify cancer patients at risk of neutropenic sepsis, while ACORN™ is a web-based digital triage platform for acute oncology. A third product, ARC™, applies the Aster platform to nuclear emergency preparedness for the NATO Alliance. All products are currently in development and have not yet received regulatory authorisation or been commercially launched.

Product overview

52 North Health is a med-tech company offering a portfolio of in-vitro diagnostic and digital solutions built on its proprietary Aster™ platform technology. The core product portfolio includes Neutrocheck®, a portable finger-prick blood test for cancer patients at risk of neutropenic sepsis, and ACORN™, a digital triage platform for acute oncology. A newer product, ARC™, extends the Aster™ platform for radiation sickness monitoring in defence applications. All products are designed to transform emergency care pathways by enabling remote patient monitoring and reducing unnecessary hospital admissions. Products mentioned on the site are in development and have not been authorised by regulators.

Differentiator

Problem solved

Functional benefit

Brands

• Neutrocheck®: A portable finger-prick blood test and app designed to help identify immunosuppressed patients who are at risk of neutropenic sepsis. The device detects biomarkers from a biological specimen and is accompanied by an app to assist patient decision-making.
• ACORN™
• Aster™
• ARC™

Products and services

• Neutrocheck® A portable finger-prick blood test and companion app that simultaneously measures neutrophil count and C-reactive protein (CRP) to identify immunosuppressed cancer patients at risk of neutropenic sepsis, enabling remote triage by clinicians and earlier antibiotic treatment. Targeted at NHS trusts, oncology services and patients undergoing chemotherapy.
• ACORN™ A web-based digital triage platform for acute oncology that provides real-time communication, built-in phone and messaging features, clinical decision support and AI-driven prioritisation tools for cancer nurses and patients managing emergency care needs.
• ARC™ A diagnostic product for nuclear emergency preparedness that enables remote triaging and treatment monitoring of individuals at risk of radiation sickness, ensuring rapid access to life-saving drugs. Developed for NATO alliance military and defence health stakeholders.
• Aster™ Platform (co-development and licensing) The world's first portable platform for cell measurement, offered for strategic co-development and licensing to pharmaceutical companies and diagnostics firms to support drug development, drug safety monitoring, drug targeting, and clinical trial endpoint measurement (e.g., co-development with a leading global diagnostics company on a platelet measurement product).

Quantifiable outcome

• 1 in 2 patients have normal neutrophils and may not have needed to attend the ER - significant reduction in unnecessary hospital visits
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

15 partnerships are on record, tiered core, major and minor.

• Cambridge University Hospitals NHS Foundation TrustcoreStrategic or Co-development Partner21-month collaboration partner for Neutrocheck clinical trials. Partnered with 52North, Macmillan, UK Sepsis Trust, UnifAI Technology for £1.2M Innovate UK Smart Grant project.
• UK Sepsis TrustmajorStrategic or Co-development Partner21-month collaboration partner for Neutrocheck expansion and clinical trials. Partnership aims to provide early identification of patients at risk of neutropenic sepsis and help save lives.
• UnifAI TechnologymajorStrategic or Co-development Partner21-month collaboration partner for Neutrocheck solution expansion. Part of £1.2M Innovate UK Smart Grant collaboration.
• East of England Cancer AlliancecoreStrategic or Co-development PartnerCollaborative partner in development of ACORN digital triage platform. Built ACORN in collaboration with East of England Cancer Alliance and with NIHR support.
• University of CambridgecoreStrategic or Co-development Partner52North spun out from University of Cambridge in 2018 by postgraduates. Ongoing research partnerships including KTP collaboration with Sormanni lab in Department of Chemistry. Cambridge Enterprise led £1M investment and continues to support 52North's journey.
• Imperial College LondonmajorStrategic or Co-development PartnerStrategic partnership with renowned UK research institution demonstrating commitment to fostering innovation in MedTech.
• Histoindex Pte LtdminorOthersCompany chaired by John Jeans CBE, newly appointed Chair of 52North. John brings extensive leadership experience from this and other medtech companies.
• Digital Health and Care Innovation CenterminorOthersOrganization chaired by John Jeans CBE, newly appointed Chair of 52North. Connection through board leadership expertise.
• Singapore Government's Diagnostics HubminorOthersJohn Jeans CBE co-chairs Singapore Government's Diagnostics Hub, bringing international strategic perspective to 52North.
• Texas Medical Center Innovation (TMCi)majorStrategic or Co-development Partner52North selected for prestigious digital health accelerator to refine US go-to-market plan. Gains access to TMCi's remarkable facilities, cutting-edge infrastructure, extensive network, and curated programming.
• Cedars-Sinai AcceleratormajorStrategic or Co-development PartnerSelected for 9th class of Cedars-Sinai Accelerator. Three-month programme offering mentorship, $100,000 investment, and hands-on experience from Cedars-Sinai experts.
• Global Pharmaceutical CompanycoreStrategic or Co-development PartnerStrategic collaboration signed with a global pharmaceutical company, mentioned in December 2024 announcement. Partnership will enable product pipeline expansion using Aster platform technology.
• Leading Diagnostic CompanycoreStrategic or Co-development PartnerWorking with one of the world's leading diagnostic companies to co-develop a new product that can remotely measure platelets using the Aster platform.
• Nordic Mentor Network for Entrepreneurship (NOME)majorStrategic or Co-development PartnerWon NOME Startup Competition 2024 securing DKK 50,000 prize and admission into renowned NOME Mentoring Program. Programme connects startups with top-tier professionals for regulatory compliance, pricing strategies, market access, and business modelling expertise.
• Renishaw plcminorOthersJohn Jeans CBE serves on board of Renishaw plc (LSE: RSW; £2bn market cap). Connection through board leadership expertise.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Abingdon Health: UK-based lateral flow diagnostics contract developer and product company. Directly comparable to 52North in core lateral flow technology, point-of-care diagnostic focus, and target customer base (healthcare providers and consumer health).
• Mologic: UK-based rapid diagnostics developer specializing in lateral flow and point-of-care tests, including at-home and clinical settings. Comparable lateral flow technology stack and focus on accessible, low-cost diagnostics for global health.
• Angle plc: UK-based liquid biopsy and cancer diagnostics company. Comparable as a UK oncology diagnostics developer pursuing FDA and CE marked approvals, serving similar oncology clinical research and clinical use cases.
• VolitionRx: Multinational cancer diagnostics developer focused on blood-based biomarker tests for oncology. Comparable in mission (blood-based cancer diagnostics) and commercial-stage medtech execution against large incumbents.
• QuantuMDx: UK-based developer of rapid point-of-care molecular diagnostic devices. Comparable in mission (portable, rapid diagnostics) and customer base (NHS trusts, global health), with similar device-plus-consumable revenue model.
• Oncimmune Holdings: UK-based immunodiagnostics company developing blood-based tests for early cancer detection. Comparable in oncology-focused blood diagnostics commercial model and NHS-aligned customer base.

Regional players

• Owlstone Medical: Cambridge, UK-based diagnostics company developing breath-based biomarker tests for cancer and other diseases. Comparable as a Cambridge spin-out diagnostics company pursuing non-invasive, decentralised diagnostic testing.

Broad incumbents

• Roche Diagnostics: Global leader in in-vitro diagnostics and point-of-care testing. Represents the established incumbent whose lateral flow and immunoassay infrastructure 52North is ultimately competing with for hospital and clinical diagnostics budgets.
• Abbott Point of Care: Major diagnostics incumbent with i-STAT and other bedside/point-of-care platforms used in hospitals globally. Comparable as the type of established platform 52North's Neutrocheck would compete with once commercialized.

Emerging players

• Cizzle Biotech: UK early-stage cancer diagnostics developer focused on blood-based biomarker detection. Comparable as a small UK oncology diagnostics player working toward commercialization through NHS and global channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/52north

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds10 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 52 North Health